000			03218cam a2200361 a 4500
003			EG-GiCUC
005			20250223032919.0
008			220212s2022 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.09.Ph.D.2022.Ro.P
100	0		_aRofida Abdalla Saleh
245	1	4	_aThe potential neuroprotective effect of a dipeptidyl peptidase-4 inhibitor and peganum harmala extract in an experimental model of Alzheimer{u2019}s disease / _cRofida Abdalla Saleh ; Supervised Dalaal Mostafa Abdallah , Hanan Salah Eldeen Elabhar , Muhammed Abdellatif Saad
246	1	5	_aالقدرة الواقية للأعصاب لأحد مثبطى إنزيم ديبيبتيديلبيبتيديز-٤ وخلاصة السذب البرى فى نموذج تجريبي لمرض الزهايمر
260			_aCairo : _bRofida Abdalla Saleh , _c2022
300			_a139 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department Pharmacology and Toxicology of
520			_aPeganumharmala (Ph) is a folk medicinal herb used in the Sinai Peninsula (Egypt) as a remedy for central disorders. The main constituents, harmine and harmaline, have displayed therapeutic efficacy against Alzheimer{u2019}s disease (AD) owing to their anticholinesterase activity; however, the herb potential on sensitizing central insulin to combat AD remains to be clarified. The current study aimed to explore the anti-amnesic effects of the methanolic Ph seed extract through moderating insulin signaling cascade, and comparing the results to a well-established dipeptidyl-peptidase (DPP)-4 antidiabetic, saxagliptin (SAX), while expanding on its mechanism, as well. Rats were allocated into normal control (NC), NC receiving SAX or the extract per se, AD model induced by aluminum chloride (AlCl3; 50 mg/kg/day; i.p) for six consecutive weeks, and AD model co-administered with SAX (3mg/kg; p.o) or with methanolic standardized Ph seed extract (187.5 mg/kg; p.o) starting 2 weeks post AlCl3. Both treatments enhanced cognition appraised by Y-maze, novel object recognition test and Morris water maze tests and improved histopathological structures altered by AlCl3. Additionally, they heightened the hippocampal contents of glucagon-like peptide (GLP)-1 and insulin, but abated insulin receptor substrate-1 phosphorylation at serine 307 (pS307-IRS-1). Besides, the two agents increased phosphorylated Akt at serine 473 (pS473-Akt) and glucose transporter type (GLUT)4. They also curtailed the hippocampal content of beta amyloid (AÝ)42, glycogen synthase (GSK)-3Ý and phosphorylated tau. They also enhanced Nrf2, while reduced lipid peroxides and replenished glutathione
530			_aIssued also as CD
650		0	_aGLP
653		4	_aAlzheimer{u2019}s disease
653		4	_aPeganum harmala
653		4	_aSaxagliptin
700	0		_aDalaal M. Abdallah , _eSupervisor
700	0		_aHanan S. Elabhar , _eSupervisor
700	0		_aMuhammed A. Saad , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c84186 _d84186